

Form PTO-449

Docket Number (Optional)  
MSA-017.02(20974-1702)Application Number  
09/578,534

RECEIVE

P. INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Crossman et al.

Filing Date

May 24, 2000

Group Art Unit  
1645

SEP 13 2001

## U.S. PATENT DOCUMENTS

TECH CENTER 1600/2

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CH	AA 4,582,788	04/15/86	Erlich	435	6	01/ 07/ 83
	AB 4,623,619	11/18/86	Owerbach et al.	435	6	02/ 18/ 83
	AC 4,666,828	05/19/87	Gusella	435	6	08/ 15/ 84
	AD 4,801,531	01/31/89	Frossard	435	6	09/ 30/ 85
	AE 4,965,188	10/23/90	Mullis et al.	435	6	06/ 17/ 87
	AF 5,110,920	05/05/92	Erlich	536	27	08/ 30/ 88
	AG 5,268,267	12/07/93	Smith	435	6	11/ 01/ 89
CH	AH 5,554,509	09/10/96	Collucci et al.	435	6	01/ 26/ 96

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
					YES	NO

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

CH	AI	Alexander R. W., "Inflammation and Coronary Artery Disease ", The New England Journal of Medicine, 331(7): 468-469 (1994).
	AJ	Anderson & King, "Modern Approaches to the Diagnosis of Coronary Artery Disease", Am. Heart J. 123(5): 1312-1323 (1992)
	AK	Badimon, et al., " Coronary Atherosclerosis: A Multifactorial Disease", Supplement II Circulation, 87 (3): II-3 -II -16 (1993).
	AL	Clark, et al., "Genomic Sequence for Human Prointerleukin 1 beta: Possible Evolution from a Reverse Transcribed Prointerleukin 1 alpha gene", Nuc. Acids Res. 14 (20) : 7897- 7914 (1986). Erratum in Nuc. Acids Res. 15 (2):868 (1987).
	AM	Clay, et al., "Interleukin 1 Receptor Antagonist Gene Polymorphism Association with Lichen Sclerosus", Hum. Genet. 94 : 407-410 (1994).
	AN	Clay, et al., " Novel Interleukin-1 Receptor Antagonist Exon Polymorphisms and their use in Allele-specific mRNA Assessement", Hum. Genet. 97 (6): 723-726 (June 1996).
	AO	di Giovine et al., "Single Based Polymorphism at -511 in the Human Interleukin -1 $\beta$ Gene (IL 1 $\beta$ )", Human Molecular Genetics 1 (6) : 450 (1992).
	AP	Dinarello, et al., "Anticytokine Strategies in the Treatement of the Systemic Inflammatory Response Syndrome", JAMA, 269(14) 1829-1835 (1993).
CH	AQ	Dinarello, et al., "The Role of Interleukin-1 in Disease", The New England Journal of Medicine 328(2): 106- 113 (Jan. 1993).

Form PTO-1449

## INFORMATION DISCLOSURE CITATION

ON APPLICATION  
(Use several sheets if necessary)

JAN 08 2002

Docket Number (Optional)  
MSA-017.02Application Number  
09/578,534Applicant  
Crossman et al.Filing Date  
May 24, 2000Group Art Unit  
1655

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
CA	WO 98/40517	9/17/98	PCT				

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

CB	Francis, S.E. et al. (1999), <i>Interleukin-1 Receptor Antagonist Gene Polymorphism and Coronary Artery Disease</i> , CIRCULATION 99(7):861.
CC	Kastrati, A. et al. (2000), <i>Protection Against Restenosis From an Interleukin-1 Receptor Antagonist Gene Polymorphism in Patients Treated With Coronary Stenting</i> , J. AM. COLLEGE CARDIOLOGY 35(2):36A.
CD	Kornman, K.S. et al. (1999), <i>Interleukin-1 Genotypes and the Association Between Periodontitis and cardiovascular Disease</i> , J. PERIODONT. RES. 34:353.
CE	Zee, R. et al. (1999), <i>Genetic Risk Factors for Post-PTCA Restenosis: A Comprehensive Analysis of Multiple Candidate Genes</i> , CIRCULATION 110(18):755.

EXAMINER

DATE CONSIDERED

Cale Myers

11-14-02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

CH	AR	Duff, "Molecular Genetics of Cytokines", The Cytokine Handbook(1994) 2:21-30.
	AS	Galea, et al., "Interleukin-1 $\beta$ in Coronary Arteries of Patients With Ischemic Heart Disease", Ath. Thromb. And Vasc. Biol., 16(8): 1000- 1006 (Aug. 1996).
	AT	Hasdai, et al., "Increased Serum Concentrations of Interleukin- 1 $\beta$ in Patients with Coronary Artery Disease", Heart, 76: 24-28 (1996).
	AU	Knox, "Discovery may help battle heart attacks", Houston Chronicle(1/10/96).
	AV	Liuzzo, et al., "The Prognostic Value of C-reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina", N.E.J.M. 331(7): 417-424 (1994).
	AW	Mansfield et al., "Novel Genetic Association Between Ulcerative Colitis and the Anti-inflammatory Cytokine Interleukin- 1 Receptor Antagonist", Gastroenterology 106 (3):637-642 (1994).
	AX	Munro & Cotran, "Biology of Disease ; The Pathogenesis of Atherosclerosis: Atherogenesis and Inflammation", Lab. Invest. 58(3):249- 261.
	AY	Nicklin, et al., "A Physical Map of the Region Encompassing the Human Interleukin-1 $\alpha$ , Interleukin-1 $\beta$ , and Interleukin-1 Receptor Antagonist Genes", Genomics 19: 382- 384 (1994).
	AZ	Tarlow, et al., "Polymorphism in Human IL -1 Receptor Antagonist Gene Inton 2 is caused by Variable Numbers of an 86- bp Tandem Repeat", Hum. Genet. 91: 403-404 (1993).
	BA	Tarlow, et al., "Severity of Alopecia Areata Is Associated with a Polymorphism in the Interleukin -1 Receptor Antagonist Gene", J. Invest. Dermatol. 103: 387- 390 (1994).
	BB	Cox et al.; "An Analysis of Linkage Disequilibrium in the Interleukin-1 Gene Cluster, Using a Novel Grouping Method for Multiallelic Markers", Am. J. Hum. Genet. 62: 1180-1188, ( 1998)
	BC	Libby Peter, MD; "From Bench to Bedside: Molecular Bases of the Acute Coronary Syndromes", Circulation, 91(11): 2844-2850, (June 1, 1995)
	BD	Ross Russell; "The Pathogenesis of Artherosclerosis: A Perspective for the 1990s ", Nature, 362: 801-809, (April 29, 1993)

EXAMINER

Cale Myers

DATE CONSIDERED

11-13-02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

RECEIVED

SEP 13 2001

TECH CENTER 1600/2900